What question did this study set out to answer?

To determine whether routine quantitative viral monitoring and preemptive rituximab prevent Epstein-Barr virus–lymphoproliferative disease (EBV-LPD) and associated mortality in high-risk stem cell transplant recipients.

June 15, 2002BloodOpen Access

Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

View Full Paper

Ask AI

Bookmark

Authors

JEJoost W. J. van EsserAmphia Ziekenhuis HNHubert G.M. NiestersCalifornia Institute of Technology BHBronno van der HoltHovon

Discussion

Member takes

Implication

Prospective cohort study demonstrates that preemptive rituximab prevents EBV-lymphoproliferative disease and mortality after allogeneic stem cell transplantation, highlighting the value of viral...

Key Points

To determine whether routine quantitative viral monitoring and preemptive rituximab prevent Epstein-Barr virus–lymphoproliferative disease (EBV-LPD) and associated mortality in high-risk stem cell transplant recipients.
Monitored 49 recipients of partially T-cell-depleted allogeneic stem cell transplants weekly for EBV reactivation using quantitative real-time PCR.
Administered preemptive therapy with a single infusion of rituximab to patients exhibiting EBV reactivation of ≥ 1000 genome equivalents/mL (received by 15 of 17 eligible patients).
Compared prospective clinical outcomes to an historical control cohort monitored retrospectively under similar high-risk conditions.
Preemptive rituximab induced complete viral clearance and prevented EBV-LPD in 14 of 15 patients after a median of 8 days (range, 1–46 days).
EBV-LPD incidence at 6 months decreased to 18% ± 9% in the prospective cohort compared with 49% ± 11% in the historical cohort.
EBV-LPD-associated mortality at 6 months was reduced to 0% in prospective patients versus 26% ± 10% in historical controls (P = .04).

Cite This Study

Esser et al. (2002) studied this question.

synapsesocial.com/papers/6a1069d44fb650da4fff6daa https://doi.org/10.1182/blood.v99.12.4364

View Full Paper

Ask AI

Bookmark

Implication

Prospective cohort study demonstrates that preemptive rituximab prevents EBV-lymphoproliferative disease and mortality after allogeneic stem cell transplantation, highlighting the value of viral...

Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

Discussion

Member takes

Implication

Key Points

Cite This Study

Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider